NT5C2 S445F

CI-VAR-00004067Explore in graph →CIViC 2897

Curated evidence

Evidence by cancer (3 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–3 of 3 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Childhood Acute Lymphoblastic Leukemia3
NT5C2 S445F	(prognostic)	Prognostic	C	Supports Poor Outcome	2	accepted	EID7864 71 Childhood B-cell acute lymphocytic leukemia relapse patients had their diagnosis and relapse samples sequenced for NT5C2 mutations. Sequencing revealed an early relapse case with NT5C2 S445F enrich… (full text at CIViC) PMID 23377183 · Meyer et al., 2013 · Open in CIViC	civic
NT5C2 S445F	Cytarabine + Doxorubicin + Gemcitabine + PrednisoloneSubstitutes	Predictive	D	Does Not Support Resistance	4	accepted	EID7817 Overexpression of NT5C2 S445F in Reh cells resulted in no change in response to cytarabine, gemcitabine, doxorubicin or prednisolone versus wildtype or GFP controls as indicated by similar apoptosis. PMID 23377183 ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.